Log in
OTCMKTS:PHGUF

Pharming Group Stock Forecast, Price & News

$1.38
+0.18 (+15.00 %)
(As of 11/27/2020 12:00 AM ET)
Add
Compare
Today's Range
$1.37
Now: $1.38
$1.38
50-Day Range
$1.07
MA: $1.15
$1.28
52-Week Range
$0.83
Now: $1.38
$1.82
Volume5,654 shs
Average Volume11,756 shs
Market Capitalization$863.71 million
P/E Ratio19.72
Dividend YieldN/A
Beta1.65
Pharming Group N.V., a specialty pharmaceutical company, develops and manufactures biopharmaceutical products in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema in Europe, the United States, Israel, and South Korea. It also engages in the development of recombinant human factor VIII (rhFVIII) for the treatment of haemophilia A; and protein replacement treatments for enzyme-deficiency disorders, such as pompe and fabry diseases, as well as products for acute kidney injury. The company has partnerships with China State Institute of Pharmaceutical Industry and the Chengdu Institute of Biological Products for the development of new products; and development collaboration and license agreement with Novartis to develop and commercialize leniolisib (CDZ173), a small molecule phosphoinositide 3-kinase delta inhibitor to treat patients with activated phosphoinositide 3-kinase delta syndrome. Pharming Group N.V. is headquartered in Leiden, the Netherlands.
Read More
Pharming Group logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 3.1 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.07 out of 5 stars


Industry, Sector and Symbol

Industry Tobacco products
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:PHGUF
CUSIPN/A
CIKN/A
Phone31-0-71-524-7400
Employees212

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$189.30 million
Cash Flow$0.09 per share
Book Value$0.19 per share

Profitability

Net Income$40.54 million

Miscellaneous

Market Cap$863.71 million
Next Earnings Date12/3/2020 (Estimated)
OptionableNot Optionable
$1.38
+0.18 (+15.00 %)
(As of 11/27/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PHGUF News and Ratings via Email

Sign-up to receive the latest news and ratings for PHGUF and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Pharming Group (OTCMKTS:PHGUF) Frequently Asked Questions

How has Pharming Group's stock price been impacted by Coronavirus?

Pharming Group's stock was trading at $1.35 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, PHGUF stock has increased by 2.2% and is now trading at $1.38.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Pharming Group?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pharming Group in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Pharming Group
.

What stocks does MarketBeat like better than Pharming Group?

Wall Street analysts have given Pharming Group a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Pharming Group wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Pharming Group's next earnings date?

Pharming Group is scheduled to release its next quarterly earnings announcement on Thursday, December 3rd 2020.
View our earnings forecast for Pharming Group
.

How were Pharming Group's earnings last quarter?

Pharming Group (OTCMKTS:PHGUF) issued its quarterly earnings data on Thursday, March, 5th. The biotechnology company reported $0.05 earnings per share for the quarter, beating analysts' consensus estimates of $0.04 by $0.01. Pharming Group had a net margin of 22.82% and a return on equity of 37.38%.
View Pharming Group's earnings history
.

Who are some of Pharming Group's key competitors?

Who are Pharming Group's key executives?

Pharming Group's management team includes the following people:
  • Dr. Sijmen de Vries M.B.A., M.D., MBA, Chairman of Management Board & CEO (Age 61)
  • Dr. Bruno M. L Giannetti, Chief Medical Officer & Member of Management Board (Age 68)
  • Ms. Mireille Sanders M.Sc., Sr. VP of Operations (Age 52)
  • Dr. Pericles Calias, Chief Scientific Officer (Age 52)
  • Susanne Embleton, Investor Relations Mang.
  • Ms. Anne-Marie de Groot, Sr. VP of Organisational Devel. (Age 39)
  • Mr. Paul Th. Jansse, VP & Head of Non-US Commercial Operations (Age 51)
  • Mr. Stephen Toor, Sr. VP & GM of Americas Region (Age 49)

What is Pharming Group's stock symbol?

Pharming Group trades on the OTCMKTS under the ticker symbol "PHGUF."

How do I buy shares of Pharming Group?

Shares of PHGUF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Pharming Group's stock price today?

One share of PHGUF stock can currently be purchased for approximately $1.38.

How big of a company is Pharming Group?

Pharming Group has a market capitalization of $863.71 million and generates $189.30 million in revenue each year. The biotechnology company earns $40.54 million in net income (profit) each year or $0.06 on an earnings per share basis. Pharming Group employs 212 workers across the globe.

What is Pharming Group's official website?

The official website for Pharming Group is www.pharming.com.

How can I contact Pharming Group?

Pharming Group's mailing address is Darwinweg 24, Leiden P7, 2333 CR. The biotechnology company can be reached via phone at 31-0-71-524-7400 or via email at [email protected]

This page was last updated on 11/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.